Skip to main content

Table 2 PS-matched HRs for association between SGLT2is versus DPP4is and risk of respiratory events and its components

From: Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study

 

No. of events

Person-years

Incidence rate per

1000 person-years

Rate difference per

1000 person-years (95% CI)

Hazard ratioa

(95% CI)

Respiratory eventsb

 SGLT2i

1025

225,583

4.54

(4.27 to 4.83)

 − 3.00

(− 3.44 to − 2.55)

0.60

(0.55 to 0.64)

 DPP4i

1810

240,013

7.54

(7.20 to 7.90)

0.00

(Ref)

1.00

(Ref)

Acute pulmonary edema

 SGLT2i

26

226,468

0.11

(0.08 to 0.17)

 − 0.21

(− 0.29 to − 0.12)

0.35

(0.23 to 0.55)

 DPP4i

78

241,692

0.32

(0.26 to 0.40)

0.00

(Ref)

1.00

(Ref)

ARDS

 SGLT2i

7

226,478

0.03

(0.01 to 0.06)

 − 0.04

(− 0.08 to 0.00)

0.44

(0.18 to 1.05)

 DPP4i

17

241,758

0.07

(0.04 to 0.11)

0.00

(Ref)

1.00

(Ref)

Pneumonia

 SGLT2i

984

225,605

4.36

(4.10 to 4.64)

 − 2.74

(− 3.18 to − 2.31)

0.61

(0.56 to 0.66)

 DPP4i

1706

240,090

7.11

(6.78 to 7.45)

0.00

(Ref)

1.00

(Ref)

Respiratory failure

 SGLT2i

28

226,467

0.12

(0.09 to 0.18)

 − 0.13

(− 0.21 to − 0.05)

0.49

(0.31 to 0.76)

 DPP4i

61

241,730

0.25

(0.20 to 0.32)

0.00

(Ref)

1.00

(Ref)

  1. ARDS acute respiratory distress syndrome, CI confidence interval, DPP4i dipeptidyl peptidase-4 inhibitor, HR hazard ratio, PS propensity score, SGLT2i sodium-glucose cotransporter 2 inhibitor
  2. aUsers of SGLT2is were propensity-score matched to users of DPP4is in a 1:1 ratio
  3. bDefined as a composite end point of acute pulmonary edema, acute respiratory distress syndrome, pneumonia, or respiratory failure